European Psychiatry - Volume 33 - March 2016

507 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S503
Conclusions Our findings indicate that the RM ≥ 20% W2 alone
and in combination with RC may be useful in the prediction of
response to SSRIs. Serum/plasma BDNF did not show strong pre-
dictive potential.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Acknowledgements This study was supported by the grants of MZ
CR No. AZV 15-29900A, MH CZ - DRO (NIMH-CZ, 00023752) and
projects National Institute of Mental Health (NIMH-CZ) number
ED2.1.00/03.0078 and the European Regional Development Fund.
EV482
Seasonal affective disorder associate
with common chronic diseases and
symptoms in a population-based
study
S. Basnet ∗, I. Merikanto , T. Lahti , T. Partonen
1 National Institute for Health and Welfare THL, Department of
Health, Helsinki, Finland
2 National Institute for Health and Welfare-Helsinki Finland,
Department of Health, Helsinki, Finland
3 University of Health, Public health, Helsinki, Finland
∗ Corresponding author.
Background Seasonal affective disorder (SAD) is a recurrent
mood disorder with 22%–42% of the patients experiencing symp-
toms even after 5–11 years after diagnosis, and 33%–44%
developing non-seasonal symptoms. The purpose of this study was
to assess how seasonality is associated with some of the most
common non-communicable diseases in the general Finnish pop-
ulation.
Methods The global seasonality score (GSS) and the experiences
of problems due to the seasonal variations from FINNRISK 2012
dataset were used to measure the seasonality in 4689 Finns aged
25–74 years living in five geographical regions in Finland, and
assess their association with common non-communicable diseases
(NCDs). The regression models and odds ratios were adopted to
analyze the associations adjusted for covariates.
Results The prevalence of SAD in the Finnish general population
is 21%. Seventy percent of the participants had seasonal variations
in sleep duration, social activity, mood and energy level, while 40%
had seasonal variations is weight and appetite. Angina pectoris and
depression were significantly associated with seasonality, includ-
ing seasonal variations in sleep duration, mood, weight, appetite,
social activity and energy level. Depression was significantly asso-
ciated with the increased odds for experiencing a problem due to
the seasonal variations (OR = 4.851, P < 0.0001) and SAD symptoms
(OR = 4.075, P < 0.0001), and with the GSS (P< 0.0001).
Conclusion Our data suggest that seasonality is associated with
depression and angina pectoris. The co-occurrence of the seasonal
variations in mood and behavior with common NCDs warrants the
need for future research to have insights into the etiology and
potentially shared pathways and mechanisms of action.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV483
The presence of chronic pain in
patients with major depressive
disorder and its inter-correlation
B. Batinic ∗, J. Nesvanulica , I. Stankovic
1 Clinic of Psychiatry- Clinical Centre of Serbia, Faculty of Philosophy-
Department of Psychology, Belgrade, Serbia
2 Faculty of Philosophy, Department of Psychology, Belgrade, Serbia
∗ Corresponding author.
Introduction Chronic pain is a common experienced symptom
among patients diagnosed with major depressive disorder (MDD).
The intensity of depression and chronic pain inter-correlated, hav-
ing negative impact on the daily functioning of the patients.
Objectives Our aim was to explore the presence of chronic pain
in patients diagnosed with MDD (single episode or recurrent),
correlation between intensity of depression and chronic pain, its
interference on daily functioning, as well as sex differences regard-
ing the explored variables.
Methods The study sample consisted of 51 (62.2%) female and 31
(37.8%) male patients diagnosed with MDD (n = 82), aged between
18 and 65 years old (mean age of 46.21). Assessment instruments
included The Beck Depression Inventory-II (BDI-II), The Brief Pain
Inventory-Short Form (BPI) (consisting of BPI-I factor of pain inten-
sity, and BPI-II-factor of pain interference with daily functioning),
and semistructured questionnaire for sociodemographic character-
istics.
Results The presence of chronic pain was found in the 51 (62,
2%) of patients with MDD. The mean score on the BDI-II for the
whole sample was 22.5 (SD 12.8). There was a positive correlation
between intensity of depression (BDI-II) and intensity of chronic
pain (BPI-1), and its interference on the level of daily function-
ing (BPI-2) (P < 0.01). Women diagnosed with MDD experienced
chronic pain of higher intensity and with greater interference on
daily functioning.
Conclusion Our research data show a high frequency of chronic
pain among patients diagnosed with MDD and its positive inter-
correlation which results in negative impact on daily functioning,
especially in females.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV484
Augmentation strategies in the
treatment of major depressive
disorder
S. Bise ∗ urtovic Begic Cemalovic
1 Psychiatric Hospital, women, Sarajevo, Bosnia and Herzegovina
2 Psychiatric Hospital, Intensive care, Sarajevo, Bosnia and
Herzegovina
∗ Corresponding author.
Augmentation strategies for the treatment of Major depressive
disorder (MDD) are needed when patients with MDD have a par-
tial, or not responded to antidepressant monotherapy. The focus
of augmentation therapy has been combining an antidepressant
(AD) medication with another AD. Atypical antipsychotics (AAP)
are becoming commonly used to augment antidepressants. Beyond
AD and AAP, alternative augmentation strategies includemood sta-
bilizers (MS).
Aim To analyze the characteristics of therapy in patients with
diagnosis of MDD and to investigate the frequency of augmentation
therapy.
Method Study included 28 patients hospitalized during one year
withMDDdiagnosis. Statistical analysiswas performedwith x2 and
t-test.
Result Among patients withMDD therewere 18 (64.28%) women
with an average age 57.5 and 10 (35.71%) men with an average
age 53.5. Of the 28 patients with MDD, 25 (89.28%) were treated
with a combination therapy, and monotherapy in the remaining 3
patients (10.71%). Of 25 patients with augmentation strategy treat-
ment, 22 (88%) used two medications and the remaining 3 (12%)
tree psychotropic medications (AAP, AD, MS). The most frequent
combinations were a combination of AD and AAP (17 patients, 68%).
Beyond that frequent combination were AD and MS (6 patients,
24%). Two patients used combination two AAP, and one patient
with two AD and one patients used AAP and MS.